Vasculitis & polymyalgia rheumatica
De novo manifestations during adalimumab treatment in Behçet’s syndrome
Authors' conclusion
De novo manifestations were infrequent (4%) among BS patients treated with adalimumab. Of these, 57% were major organ involvement, mainly vascular involvement. None of the patients developed posterior uveitis.
Study context
- Population
- All Behçet's syndrome (BS) patients who received adalimumab in one centre between 2008 and 2023
- Participants
- 335 patients
- Outcome
- Frequency of de novo manifestations (new BS manifestations occurring for the first time) during adalimumab treatment
Methodological detailschart review, single-centre
- Chart review
- Single-centre
Main finding
As reported in the abstract
De novo manifestation during adalimumab
- Patients with a de novo manifestation
- 14 (4%)
- Vascular involvement
- 5
- Arthritis
- 3
- Anterior uveitis
- 2
- Nervous system involvement
- 2
- Gastrointestinal involvement
- 1
- Epididymitis
- 1
- Major organ involvement among de novo manifestations
- 57%
- Posterior uveitis
- 0
Observational data: associations, not effects.
Further findings
Management of de novo manifestations
- Switched to another biologic
- 4
- Dose intensified
- 3
- Colchicine, conventional immunosuppressives and/or GC added
- 5
- Topical eye drops added
- 2
- Remission of de novo manifestations in all patients
Original publication
De novo manifestations during adalimumab treatment in Behçet’s syndrome. Rheumatology (Oxford). Published 7 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →